14:10 uur 22-02-2022

Exscientia presenteert op komende beleggersconferenties in maart

OXFORD, Engeland–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) heeft vandaag aangekondigd dat Andrew Hopkins, DPhil., oprichter en CEO van Exscientia, en Ben Taylor, CFO & Chief Strategy Officer, zullen deelnemen aan open haardchats op de volgende investeerdersconferenties in maart :

Morgan Stanley EMEA HealthTech-conferentie:

Datum: dinsdag 1 maart 2022

Tijd: 9.00 uur ET / 14.00 uur GMT

Locatie: virtueel

Barclays Global Healthcare-conferentie:

Datum: woensdag 16 maart 2022

Tijd: 11:15 uur ET / 16:15 uur GMT

Locatie: Miami, Florida

Live webcasts van de presentaties zullen beschikbaar zijn op de website van het bedrijf, onder de sectie “Investors & Media” op www.investors.exscientia.ai. Gearchiveerde herhalingen van de webcasts zijn ongeveer 30 dagen na de presentatie beschikbaar.

Exscientia to Present at Upcoming Investor Conferences in March

OXFORD, England–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia’s founder and CEO and Ben Taylor, CFO & Chief Strategy Officer, will participate in fireside chats at the following investor conferences in March:

Morgan Stanley EMEA HealthTech Conference:

Date: Tuesday, March 1, 2022

Time: 9:00 a.m. ET / 2:00 p.m. GMT

Location: Virtual

Barclays Global Healthcare Conference:

Date: Wednesday, March 16, 2022

Time: 11:15 a.m. ET / 4:15 p.m. GMT

Location: Miami, Florida

Live webcasts of the presentations will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects underway. By designing better drugs, faster, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Vienna, Dundee, Boston, Miami, Cambridge (UK) and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.


Sara Sherman



Amanda Galgay


Check out our twitter: @NewsNovumpr